Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tetrylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA1 known ✓ | Q09470 | 1/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.90 |
| ▸ | ATM | Q13315 | 1/20 | 0.90 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrylammonium SCHEMBL10982446 | 1.00 | KDM4E (0.90) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL9833429 | 0.95 | KDM4E (0.82) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL6461256 | 0.95 | KDM4E (0.82) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL5374883 | 0.95 | KDM4E (1.00) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL31598896 | 0.95 | TSHR (0.89) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL5374892 | 0.95 | TSHR (0.89) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL10982451 | 0.95 | TSHR (0.89) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL49847 | 0.95 | KDM4E (1.00) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL333139 | 0.95 | TSHR (0.89) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL10982449 | 0.95 | KDM4E (1.00) | KDM4EPMP22ATMTSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188006-A1 | 13C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | CHIRON AS (NO) | 2025-06-12 | — | — | US | claimed |
| EP-4493530-A1 | 13 C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | Chiron AS (NO) | 2025-01-22 | — | — | EP | claimed |
| WO-2023174709-A1 | 13C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | CHIRON AS (NO) | 2023-09-21 | — | — | WO | claimed |
| EP-4245742-A1 | 13C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | Chiron AS (NO) | 2023-09-20 | — | — | EP | claimed |
| US-3997362-A | AMMONIUM | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1976-12-14 | — | — | US | claimed |
| EP-3507316-B1 | HALOGEN AND POLYHALIDE MEDIATED PHENOLIC POLYMERIZATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4617326-A1 | DIKETOPYRROLOPYRROLE COMPOUND | DIC Corporation (JP) | 2025-09-17 | — | — | EP | disclosed |
| EP-4617325-A1 | QUINACRIDONE COMPOUND | DIC Corporation (JP) | 2025-09-17 | — | — | EP | disclosed |
| US-20250188006-A1 | 13C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | CHIRON AS (NO) | 2025-06-12 | — | — | US | disclosed |
| CN-119907833-A | Pyrrolopyrroldione compounds | DIC株式会社 | 2025-04-29 | — | — | CN | disclosed |
| CN-119604587-A | Quinacridone compounds | DIC株式会社 | 2025-03-11 | — | — | CN | disclosed |
| EP-4493530-A1 | 13 C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | Chiron AS (NO) | 2025-01-22 | — | — | EP | disclosed |
| US-6528664-B2 | Synthetic methods for polyphenols | MARS, INCORPORATED | 2003-03-04 | — | — | US | disclosed |
| EP-1027345-B1 | SYNTHETIC METHODS FOR POLYPHENOLS | MARS INC (US) | 2003-02-19 | — | — | EP | disclosed |
| US-20020128493-A1 | Coupling flavonoid-like compounds having protected hydroxy groups by functionalizing the C-4; oxidative dehydrogenation to form dimers and oligomers; efficiency; anticarciogenic agents; breast cancer | MARS, INCORPORATED | 2002-09-12 | — | — | US | disclosed |
| US-6420572-B1 | FLAVANOID DERIVATIVES AND PHENOLIC DERIVATIVES WITH HALOGENATION | MARS, INCORPORATED | 2002-07-16 | — | — | US | disclosed |
| US-6242609-B1 | AMMONIUM TRIHALIDE FOR HALOGENATION OF COLOR COUPLERS AND SILVER HALIDE EMULSIONS | KONICA CORPORATION (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1027345-A1 | SYNTHETIC METHODS FOR POLYPHENOLS | Mars Incorporated (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999019319-A1 | SYNTHETIC METHODS FOR POLYPHENOLS | MARS INCORPORATED (US) | 1999-04-22 | — | — | WO | disclosed |
| US-3997362-A | AMMONIUM | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128493-A1 | Coupling flavonoid-like compounds having protected hydroxy groups by functionalizing the C-4; oxidative dehydrogenation to form dimers and oligomers; efficiency; anticarciogenic agents; breast cancer | GPX4, NOX4, TPD52L2 | KCNA1 3762/4885KDM4E 1217/4885PMP22 4726/4885 |
| US-20250188006-A1 | 13C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | PCNA, CAT, CDC73 | KCNA1 3569/4885KDM4E 785/4885PMP22 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.